NCT06999356 Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitoring
| NCT ID | NCT06999356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sutter Health |
| Condition | Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-22 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-05-22 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this proposal is to determine the impact of a produce prescription program in predominantly Hispanic/Latino adults with established non-insulin treated T2D and an HbA1c at or above 9%.
Eligibility Criteria
Inclusion Criteria: Adults (aged\>18 years) with established T2D and HbA1c of 9% or higher per most recent test result within the last 6 months. Agreement to only track glucose levels via study-provided CGM - Exclusion Criteria: Type 1 diabetes, Insulin use, Pregnancy, Use of steroids or medications that impact glucose levels Medications Include: Atypical antipsychotics Clozapine Olanzapine Paliperidone Quietiapine Risperidone Corticosteroids Calcineurin inhibitors Cyclosporine Sirolimus Tacrolimus Protease Inhibitors Atazanavir Darunavir Fosamprenavir Indinavir Nelfinavir Ritonivir Saquinavir Tipranivir Life expectancy less than 6 months Diagnosis of stage 5 kidney disease or at risk of needing dialysis per Investigator discretion Any active clinically significant disease or disorder which in the investigator's opinion could interfere with participation in the study. Inability to follow study procedures per Investigator discretion \-
Contact & Investigator
David Kerr, PhD
PRINCIPAL INVESTIGATOR
Sutter Health
Frequently Asked Questions
Who can join the NCT06999356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06999356 currently recruiting?
Yes, NCT06999356 is actively recruiting participants. Contact the research team at David.Kerr@sutterhelath.org for enrollment information.
Where is the NCT06999356 trial being conducted?
This trial is being conducted at Santa Barbara, United States.
Who is sponsoring the NCT06999356 clinical trial?
NCT06999356 is sponsored by Sutter Health. The principal investigator is David Kerr, PhD at Sutter Health. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.